1. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004; 114:555–76.
2. Rademacher ER, Jacobs DR Jr, Moran A, Steinberger J, Prineas RJ, Sinaiko A. Relation of blood pressure and body mass index during childhood to cardiovascular risk factor levels in young adults. J Hypertens. 2009; 27:1766–74.

3. Falkner B, Lurbe E. Primary hypertension beginning in childhood and risk for future cardiovascular disease. J Pediatr. 2021; 238:16–25.

4. Falkner B, Gidding S. Life-course implications of pediatric risk factors for cardiovascular disease. Can J Cardiol. 2021; 37:766–75.

5. Wühl E. Hypertension in childhood obesity. Acta Paediatr. 2019; 108:37–43.

6. Lurbe E, Agabiti-Rosei E, Cruickshank JK, Dominiczak A, Erdine S, Hirth A, et al. 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens. 2016; 34:1887–920.

7. Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017; 140:e20171904.
8. Tran AH, Urbina EM. Hypertension in children. Curr Opin Cardiol. 2020; 35:376–80.

9. Bonito PD, Licenziati MR, Baroni MG, Maffeis C, Morandi A, Manco M, et al. The American Academy of Pediatrics hypertension guidelines identify obese youth at high cardiovascular risk among individuals non-hypertensive by the European Society of Hypertension guidelines. Eur J Prev Cardiol. 2020; 27:8–15.
10. Blanchette E, Flynn JT. Implications of the 2017 AAP clinical practice guidelines for management of hypertension in children and adolescents: a review. Curr Hypertens Rep. 2019; 21:35.

11. Rosner B, Cook N, Portman R, Daniels S, Falkner B. Determination of blood pressure percentiles in normal-weight children: some methodological issues. Am J Epidemiol. 2008; 167:653–66.

12. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Himmelfarb CD, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2018; 138:e426–83.
13. Sharma AK, Metzger DL, Rodd CJ. Prevalence and severity of high blood pressure among children based on the 2017 American Academy of Pediatrics guidelines. JAMA Pediatr. 2018; 172:557–65.

14. Khoury M, Khoury PR, Dolan LM, Kimball TR, Urbina EM. Clinical implications of the revised AAP pediatric hypertension guidelines. Pediatrics. 2018; 142:e20180245.

15. Dong Y, Song Y, Zou Z, Ma J, Dong B, Prochaska JJ. Updates to pediatric hypertension guidelines: influence on classification of high blood pressure in children and adolescents. J Hypertens. 2019; 37:297–306.
16. Al Kibria GM, Swasey K, Sharmeen A, Day B. Estimated change in prevalence and trends of childhood blood pressure levels in the United States after application of the 2017 AAP guideline. Prev Chronic Dis. 2019; 16:E12.

17. ESCAPE Trial Group, Wühl E, Trivelli A, Picca S, Litwin M, PecoAntic A, et al. Strict blood-pressure control and progression of renal failure in children. N Engl J Med. 2009; 361:1639–50.

18. Raile K, Galler A, Hofer S, Herbst A, Dunstheimer D, Busch P, et al. Diabetic nephropathy in 27,805 children, adolescents, and adults with type 1 diabetes: effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset, and sex. Diabetes Care. 2007; 30:2523–8.
19. Lurbe E, Redon J, Kesani A, Pascual JM, Tacons J, Alvarez V, et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med. 2002; 347:797–805.

20. Ho M, Garnett SP, Baur L, Burrows T, Stewart L, Neve M, et al. Effectiveness of lifestyle interventions in child obesity: systematic review with meta-analysis. Pediatrics. 2012; 130:e1647–71.

21. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007; 369:201–7.

22. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens. 2006; 24:3–10.

23. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31:1281–357.
24. Macumber I, Flynn JT. Does treatment-resistant hypertension exist in children? A review of the evidence. Pediatr Nephrol. 2020; 35:969–76.

25. White WB, Turner JR, Sica DA, Bisognano JD, Calhoun DA, Townsend RR, et al. Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive Forum held in Bethesda, MD, U.S.A., October 10th 2013. J Am Soc Hypertens. 2014; 8:743–57.
26. Ahn SY, Gupta C. Genetic programming of hypertension. Front Pediatr. 2018; 5:285.
